Emcure Pharmaceuticals Q1 FY27 Results: International Business Powers 23% Revenue Growth, PAT Jumps 36%
Emcure Pharmaceuticals Ltd. delivered a strong start to FY27, reporting robust double-digit growth in both revenue and profitability for the quarter ended June 30, 2026. The pharmaceutical major continued to benefit from its diversified international business, operational efficiencies, and improving domestic performance, while also strengthening its leadership team for the company’s next phase of growth.
Q1 FY27 Financial Highlights
Emcure reported revenue from operations of ₹2,580.4 crore, registering a 22.8% year-on-year (YoY) increase compared to ₹2,100.5 crore in Q1 FY26.
The company’s profitability improved at an even faster pace:
| Particulars | Q1 FY27 | YoY Growth |
|---|---|---|
| Revenue from Operations | ₹2,580.4 Cr | 22.8% |
| EBITDA | ₹508.0 Cr | 25.8% |
| EBITDA Margin | 19.7% | +50 bps |
| Profit Before Tax | ₹393.5 Cr | 35.3% |
| Profit After Tax | ₹292.5 Cr | 36.2% |
| PAT Margin | 11.3% | +110 bps |
The improvement in EBITDA and PAT margins reflects better operating leverage and productivity gains across the business.
International Business Continues to Lead Growth
International markets remained Emcure’s biggest growth engine during the quarter.
The international business contributed 58% of total revenue and grew 34.2% YoY, significantly outperforming the domestic business. Europe, Canada, and Rest of World (RoW) markets all delivered healthy growth.
Segment-wise Revenue Mix
- International Business: 58%
- Domestic Business: 42%
Regional Performance
- Europe: Revenue grew 32.8% YoY, supported by strong execution of the base business and increasing contribution from Liposomal Amphotericin B.
- Canada: Revenue increased 24.6% YoY through market share gains, new product launches, and one additional product approval.
- Rest of World (RoW): Revenue surged 44.8% YoY, driven by strong order execution, expansion into three new territories, and approvals for more than 15 products across Asia, Africa, and Latin America. Emcure also signed a royalty-free voluntary licensing agreement with MSD for alimatravir, a once-monthly oral PrEP candidate currently in late-stage development.
Domestic Business Remains Resilient
India business recorded 10.2% YoY growth, reflecting stable demand despite a competitive market.
Growth was driven by:
- Strong performance in CNS and women’s health portfolios
- Continued expansion in cardio-metabolic therapies
- Improved contribution from chronic therapies
- Growth of leading brands including Tenectase, Orofer XT, Orofer FCM, and Metpure
- Ongoing integration of Sanofi OAD and Roche portfolios
The company expects domestic momentum to strengthen further as its expanded sales force and product portfolio gain traction during the remainder of FY27.
Leadership Changes to Support Five-Year Growth Strategy
Emcure announced important leadership transitions aimed at strengthening long-term governance and execution.
Key developments include:
- Satish Mehta will become Chairman while continuing as Managing Director & CEO after the upcoming AGM.
- Samit Mehta has been appointed Chief Operating Officer (COO) of Emcure Pharmaceuticals with expanded responsibility for R&D, operations, and licensing.
- Gennova Biopharmaceuticals has become a wholly owned subsidiary, with Samit Mehta continuing as CEO to lead the biologics and biosimilars business.
According to the company, these changes are intended to strengthen institutional leadership and support its five-year growth roadmap.
Continued Investment in Innovation
Research and development remains one of Emcure’s key strategic priorities.
During Q1 FY27:
- R&D spending increased to ₹90.4 crore from ₹73.0 crore a year earlier.
- Capital expenditure rose to ₹116.8 crore.
- Return on Capital Employed (RoCE) remained healthy at 23.4%.
- Net debt stood at approximately ₹1,102.6 crore, with net debt to trailing EBITDA at just 0.7x, indicating a comfortable leverage position.
Management believes Emcure is well positioned for sustained growth, supported by:
- A diversified international business platform
- Continued product launches across global markets
- Expansion of chronic therapy portfolio in India
- Strong R&D pipeline
- Operational efficiencies that continue to improve margins
- Strengthened leadership structure to execute its long-term strategy
The company expects both its domestic and international businesses to continue contributing to growth over the coming quarters.